{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T03:30:03Z","timestamp":1771299003091,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T00:00:00Z","timestamp":1609804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T00:00:00Z","timestamp":1609804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Projekt DEAL"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oral Maxillofac Surg"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Malignant tumours in the parotid gland can originate either from the gland itself or as a result of metastatic spread of other tumours, such as cutaneous squamous cell carcinomas (CSCC) of the head and neck area. The aim of this study was to analyse and compare the clinical behaviour of primary as well as CSCC metastatic parotid cancers with special emphasis on therapy and oncologic outcome.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Clinical and histopathological data of 342 patients with parotid gland malignomas surgically treated in a tertiary referral centre between 1987 and 2015 were retrospectively assessed. Oncologic outcomes of all cases with CSCC metastasis of the parotid gland (<jats:italic>n<\/jats:italic> = 49) were compared to those of primary parotid gland carcinomas (<jats:italic>n<\/jats:italic> = 293).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Mean age at diagnosis was 72.3 years for CSCC patients versus 56.8 years in patients with primary parotid carcinoma. A total of 83.7% of CSCC patients were male, compared to 48.8% in the group of primary carcinomas. Forty-five out of 49 CSCC patients underwent total parotidectomy and neck dissection (91.8%). A total of 93.9% out of all CSCC patients received adjuvant radiotherapy. Five-year overall survival (OS) was 32.6% in CSCC patients versus 77.2% in primary parotid carcinoma patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>As compared to primary parotid cancers, we could show that patients suffering from CSCC metastases to the parotid gland presented with significantly higher age and worse survival.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10006-020-00934-8","type":"journal-article","created":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T07:03:03Z","timestamp":1609830183000},"page":"383-388","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Survival after parotid gland metastases of cutaneous squamous cell carcinoma of the head and neck"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4047-0678","authenticated-orcid":false,"given":"Moritz Friedo","family":"Meyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Wolber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Arolt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Wessel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Quaas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens Peter","family":"Klussmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Semrau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Beutner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,5]]},"reference":[{"key":"934_CR1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.oraloncology.2017.02.018","volume":"68","author":"G Keller","year":"2017","unstructured":"Keller G, Steinmann D, Quaas A, Gr\u00fcnwald V, Janssen S, Hussein K (2017) New concepts of personalized therapy in salivary gland carcinomas. Oral Oncol 68:103\u2013113","journal-title":"Oral Oncol"},{"key":"934_CR2","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.18632\/oncotarget.13952","volume":"8","author":"X Wang","year":"2017","unstructured":"Wang X, Luo Y, Li M, Yan H, Sun M, Fan T (2017) Management of salivary gland carcinomas - a review. Oncotarget 8:3946\u20133956","journal-title":"Oncotarget"},{"key":"934_CR3","unstructured":"El-Naggar AK, Chan JKC, Grandis JR, Takata T, Slootweg PJ (eds) (2017) WHO\u00a0classification of head and neck tumours (4th edn). Chapter 7. IARC, Lyon"},{"key":"934_CR4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/coa.12672","volume":"42","author":"MF Meyer","year":"2017","unstructured":"Meyer MF, Kreppel M, Meinrath J, Gr\u00fcnewald I, Stenner M, Drebber U, Quaas A, Odenthal M, Semrau R, Huebbers CU, Z\u00f6ller J, Huettenbrink K-B, Buettner R, Beutner D (2017) Prediction of outcome by lymph node ratio in patients with parotid gland cancer. Clin Otolaryngol 42:98\u2013103","journal-title":"Clin Otolaryngol"},{"key":"934_CR5","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1158\/1078-0432.CCR-19-3758","volume":"26","author":"M Linxweiler","year":"2020","unstructured":"Linxweiler M, Kuo F, Katabi N, Lee M, Nadeem Z, Dalin MG, Makarov V, Chowell D, Dogan S, Ganly I, Hakimi AA, Wong RJ, Riaz N, Ho AL, Chan TA, Morris ZGT (2020) The immune microenvironment and neoantigen landscape of aggressive salivary gland carcinomas differ by subtype. Clin Cancer Res 26:2859\u20132870. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3758","journal-title":"Clin Cancer Res"},{"key":"934_CR6","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/(SICI)1097-0142(19990715)86:2<207::AID-CNCR4>3.0.CO;2-Q","volume":"86","author":"JT Castle","year":"1999","unstructured":"Castle JT, Thompson LD, Frommelt RA, Wenig BM, Kessler HP (1999) Polymorphous low grade adenocarcinoma: a clinicopathologic study of 164 cases. Cancer 86:207\u2013219","journal-title":"Cancer"},{"key":"934_CR7","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/jso.2930460207","volume":"46","author":"AL Clode","year":"1991","unstructured":"Clode AL, Fonseca I, Santos JR, Soares J (1991) Mucoepidermoid carcinoma of the salivary glands: a reappraisal of the influence of tumor differentiation on prognosis. J Surg Oncol 46:100\u2013106","journal-title":"J Surg Oncol"},{"key":"934_CR8","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1186\/s12885-019-5969-6","volume":"19","author":"Q Fang","year":"2019","unstructured":"Fang Q, Wu J, Liu F (2019) Oncologic outcome and potential prognostic factors in primary squamous cell carcinoma of the parotid gland. BMC Cancer 19:752","journal-title":"BMC Cancer"},{"key":"934_CR9","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.21873\/invivo.11696","volume":"33","author":"A Franzen","year":"2019","unstructured":"Franzen A, Lieder A, Guenzel T, Buchali A (2019) Heterogenicity of parotid gland squamous cell carcinoma: a study of 49 patients. In Vivo 33:2001\u20132006","journal-title":"In Vivo"},{"key":"934_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1445-2197.1987.tb01234.x","volume":"57","author":"PJ Bergersen","year":"1987","unstructured":"Bergersen PJ, Kennedy PJ, Kneale KL (1987) Metastatic tumours of the parotid region. Aust N Z J Surg 57:23\u201326","journal-title":"Aust N Z J Surg"},{"key":"934_CR11","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1097\/00005537-200306000-00029","volume":"113","author":"LP Bron","year":"2003","unstructured":"Bron LP, Traynor SJ, McNeil EB, O\u2019Brien CJ (2003) Primary and metastatic cancer of the parotid: comparison of clinical behavior in 232 cases. Laryngoscope 113:1070\u20131075","journal-title":"Laryngoscope"},{"key":"934_CR12","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/hed.24683","volume":"39","author":"N Hirshoren","year":"2017","unstructured":"Hirshoren N, Danne J, Dixon BJ, Magarey M, Kleid S, Webb A, Tiong A, Corry J, Gyorki D (2017) Prognostic markers in metastatic cutaneous squamous cell carcinoma of the head and neck. Head Neck 39:772\u2013778","journal-title":"Head Neck"},{"key":"934_CR13","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/hed.20048","volume":"26","author":"N Audet","year":"2004","unstructured":"Audet N, Palme CE, Gullane PJ, Gilbert RW, Brown DH, Irish J, Neligan P (2004) Cutaneous metastatic squamous cell carcinoma to the parotid gland: analysis and outcome. Head Neck 26:727\u2013732","journal-title":"Head Neck"},{"key":"934_CR14","first-page":"30140","volume":"S1808\u20138694","author":"FM Girardi","year":"2019","unstructured":"Girardi FM, Wagner VP, Martins MD, Abentroth AL, Hauth LA (2019) Better outcome for parotid versus neck metastasis of head and neck cutaneous squamous cell carcinoma: a new report on reemerging data. Braz J Otorhinolaryngol S1808\u20138694:30140\u201330145","journal-title":"Braz J Otorhinolaryngol"},{"key":"934_CR15","unstructured":"Magliocca K Pathologic TNM staging of major salivary glands (AJCC 8th edition). PathologyOutlines.com website. https:\/\/www.pathologyoutlines.com\/topic\/salivaryglandsTNM.html. Accessed May 23rd, 2020"},{"key":"934_CR16","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1001\/archotol.129.7.720","volume":"129","author":"E Stennert","year":"2003","unstructured":"Stennert E, Kisner D, Jungehuelsing M, Guntinas-Lichius O, Schr\u00f6der U, Eckel HE, Klussmann JP (2003) High incidence of lymph node metastasis in major salivary gland cancer. Arch Otolaryngol Head Neck Surg 129:720\u2013723","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"934_CR17","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3109\/00016480903062160","volume":"130","author":"R Kawata","year":"2010","unstructured":"Kawata R, Koutetsu L, Yoshimura K, Nishikawa S, Takenaka H (2010) Indication for elective neck dissection for N0 carcinoma of the parotid gland: a single institution\u2019s 20-year experience. Acta Otolaryngol 130:286\u2013292","journal-title":"Acta Otolaryngol"},{"key":"934_CR18","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/lio2.326","volume":"4","author":"AS Parikh","year":"2019","unstructured":"Parikh AS, Khawaja A, Puram SV, Srikanth P, Tjoa T, Lee H, Sethi RKV, Bulbul M, Varvares MA, Rocco JW, Emerick KS, Deschler DG, Lin DT (2019) Outcomes and prognostic factors in parotid gland malignancies: a 10-year single center experience. Laryngoscope Investig Otolaryngol 4:632\u2013639","journal-title":"Laryngoscope Investig Otolaryngol"},{"key":"934_CR19","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1002\/cncr.11254","volume":"97","author":"VL Vander Poorten","year":"2003","unstructured":"Vander Poorten VL, Hart AA, van der Laan BF, Baatenburg de Jong RJ, Manni JJ, Marres HA, Meeuwis CA, Lubsen H, Terhaard CH, Balm AJ (2003) Prognostic index for patients with parotid carcinoma: external validation using the nationwide 1985-1994 Dutch Head and Neck Oncology Cooperative Group database. Cancer 97:1453\u20131463","journal-title":"Cancer"},{"key":"934_CR20","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/hed.10063","volume":"24","author":"CJ O\u2019Brien","year":"2002","unstructured":"O\u2019Brien CJ, McNeil EB, McMahon JD, Pathak I, Lauer CS, Jackson MA (2002) Significance of clinical stage, extent of surgery, and pathologic findings in metastatic cutaneous squamous carcinoma of the parotid gland. Head Neck 24:417\u2013422","journal-title":"Head Neck"},{"key":"934_CR21","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1177\/0194599816662864","volume":"155","author":"F Creighton","year":"2016","unstructured":"Creighton F, Bergmark R, Emerick K (2016) Drainage patterns to nontraditional nodal regions and level IIB in cutaneous head and neck malignancy. Otolaryngol Head Neck Surg 155:1005\u20131011","journal-title":"Otolaryngol Head Neck Surg"},{"key":"934_CR22","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1002\/hed.21574","volume":"33","author":"B Givi","year":"2011","unstructured":"Givi B, Andersen PE, Diggs BS, Wax MK, Gross ND (2011) Outcome of patients treated surgically for lymphnode metastases from cutaneous squamous cell carcinoma of the head and neck. Head Neck 33:999\u20131004","journal-title":"Head Neck"},{"key":"934_CR23","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1159\/000500636","volume":"235","author":"F Deilhes","year":"2019","unstructured":"Deilhes F, Boulinguez S, Pag\u00e8s C, Paul C, Meyer N (2019) Advanced cutaneous squamous cell carcinoma is associated with suboptimal initial management in a cohort of 109 patients. Dermatology 235:516\u2013521","journal-title":"Dermatology"},{"key":"934_CR24","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1017\/S0022215117001323","volume":"132","author":"AC Coombs","year":"2018","unstructured":"Coombs AC, Butler A, Allison R (2018) Metastatic cutaneous squamous cell carcinoma of the parotid gland: prognostic factors. J Laryngol Otol 132:264\u2013269","journal-title":"J Laryngol Otol"},{"key":"934_CR25","doi-asserted-by":"publisher","first-page":"378","DOI":"10.18632\/oncotarget.27434","volume":"11","author":"H Montaudi\u00e9","year":"2020","unstructured":"Montaudi\u00e9 H, Viotti J, Combemale P, Dutriaux C, Dupin N, Robert C, Mortier L, Kaphan R, Duval-Modeste AB, Dalle S, De Quatrebarbes J, Stefan A, Brunet-Possenti F, Kogay M, Picard-Gauci A, Poissonnet G, Peyrade F (2020) Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma: a retrospective, multicentre study. Oncotarget 11:378\u2013385","journal-title":"Oncotarget"},{"key":"934_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11864-019-0697-3","volume":"21","author":"PO de Lima","year":"2020","unstructured":"de Lima PO, Joseph S, Panizza B, Simpson F (2020) Epidermal growth factor receptor\u2019s function in cutaneous squamous cell carcinoma and its role as a therapeutic target in the age of immunotherapies. Curr Treat Options in Oncol 21:9","journal-title":"Curr Treat Options in Oncol"},{"key":"934_CR27","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/bjd.18957","volume":"183","author":"T Steeb","year":"2020","unstructured":"Steeb T, Wessely A, Heppt F, Harla\u00df M, Berking C, Heppt MV (2020) Where do we stand with immune checkpoint blockade for advanced cutaneous squamous cell carcinoma? A systematic review and critical appraisal of existing evidence. Br J Dermatol 183:380\u2013382. https:\/\/doi.org\/10.1111\/bjd.18957","journal-title":"Br J Dermatol"},{"key":"934_CR28","doi-asserted-by":"publisher","first-page":"9547","DOI":"10.1200\/JCO.2019.37.15_suppl.9547","volume":"37","author":"E Maubec","year":"2019","unstructured":"Maubec E, Boubaya M, Petrow P, Basset-Seguin N, Grob JJ, Dr\u00e9no B, Beylot-Barry M, Scheer-Senyarich I, Helfen S, Leccia MT, Stefan AR, Saiag P, de Quatrebarbes J, Meyer N, Deschamps L, Alloux C, Lopez I, Cherbal S, Tibi A, L\u00e9vy V, Groupe de Canc\u00e9rologie Cutan\u00e9e (2019) Pembrolizumab as first-line therapy in patients with unresectable cutaneous squamous cell carcinoma (cSCC): phase 2 results from CARSKIN. J Clin Oncol 37:9547","journal-title":"J Clin Oncol"},{"key":"934_CR29","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1805131","volume":"379","author":"MR Migden","year":"2018","unstructured":"Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS, Rabinowits G, Thai AA, Dunn LA, Hughes BGM, Khushalani NI, Modi B, Schadendorf D, Gao B, Seebach F, Li S, Li J, Mathias M, Booth J, Mohan K, Stankevich E, Babiker HM, Brana I, Gil-Martin M, Homsi J, Johnson ML, Moreno V, Niu J, Owonikoko TK, Papadopoulos KP, Yancopoulos GD, Lowy I, Fury MG (2018) PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med 379:341\u2013351","journal-title":"N Engl J Med"},{"key":"934_CR30","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40257-019-00426-w","volume":"20","author":"R Patel","year":"2019","unstructured":"Patel R, Chang ALS (2019) Immune checkpoint inhibitors for treating advanced cutaneous squamous cell carcinoma. Am J Clin Dermatol 20:477\u2013482","journal-title":"Am J Clin Dermatol"}],"container-title":["Oral and Maxillofacial Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10006-020-00934-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10006-020-00934-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10006-020-00934-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T04:07:29Z","timestamp":1628482049000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10006-020-00934-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,5]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["934"],"URL":"https:\/\/doi.org\/10.1007\/s10006-020-00934-8","relation":{},"ISSN":["1865-1550","1865-1569"],"issn-type":[{"value":"1865-1550","type":"print"},{"value":"1865-1569","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,5]]},"assertion":[{"value":"13 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability (software application or custom code)"}}]}}